Navigation Links
Optimization of Comparative Efficacy Trials
Date:9/19/2012

NEW YORK, Sept. 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Optimization of Comparative Efficacy Trials

http://www.reportlinker.com/p0968581/Optimization-of-Comparative-Efficacy-Trials.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

Clinicians and patients want to be able to compare new drugs with those already available to inform evidence-based medicine, and reimbursement authorities require comparative data to support their decisions. This report discusses the optimization of comparative efficacy trials, with particular attention to the question of comparator selection.Understand the role that comparative efficacy plays in the evaluation of new drugs.Identify decision-making processes for guiding key choices in the design of pivotal comparative efficacy trials.Understand the importance of comparator selection and the consequences of later disagreements with external authorities.Review the factors that need to be considered in making a comparator selection.Assess the opportunity for gaining input from drug evaluation authorities.The choice of active control group for a comparative trial can be difficult due to variation in the standard of care across different geographic regions and changing medical practicesNumerous recent appraisals by the UK's National Institute for Health and Clinical Excellence (NICE) and Germany's Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) have demonstrated the critical stance that is being readily taken by these bodies with regard to comparator selection.Scientific advice from regulators and, where possible, from health technology assessors or reimbursement authorities can be extremely useful in guiding clinical development planning, especially in the choice of comparator.How should an active comparator and other features of comparative efficacy trials be chosen?What decision-making techniques are available to those designing comparative efficacy trials?Can the range of comparators be expected to extend beyond pharmaceutical interventions?To what extent have drug evaluation committees shown flexibility in disagreements about the optimum comparator?Which regulatory and reimbursement authorities are willing to offer scientific advice in the design of a comparative efficacy trial?

 

About the author

•Disclaimer

EXECUTIVE SUMMARY

•Trial optimization

Introduction

•Key points regarding comparative efficacy trials

Trial optimization

•Introduction

•Recent examples of challenges in comparator selection

- NICE criticizes Novartis's choice of comparator for Gilenya

- AstraZeneca's Faslodex rejected by NICE on the basis of indirect comparison

- IQWiG and NICE judge GlaxoSmithKline's Benlysta to have been inadequately compared

- Biogen Idec's Fampyra highlights challenges of comparison with non-pharmacological treatment

- IQWiG disagrees with GlaxoSmithKline regarding comparators for Trobalt

- Eisai's Halaven considered inadequately compared despite following EMA protocol

- Comparison with experimental treatments not demanded by the FDA but view of reimbursers is uncertain

- A late-arriving statin has adequate comparator data for regulatory approval but proving differentiation is another matter

•Selection of active control group for the comparative trial

- Use of existing knowledge

- Decision-making techniques

- Reflecting on the range of interventions

•Patient populations, outcomes, and other study variables

•Modeling and simulation in clinical trial design

•Scientific advice

- The NICE scientific advice process

- Multi-stakeholder dialogue

•Conclusions

Appendix

•Methodology

- Research methodology

- Acknowledgements

•Glossary

•Abbreviations

•References

 

TABLES

•Table: Statins available in the US

•Table: Pharmacometric consultancies

 

FIGURES

•Figure: Factors determining choice of active control in a clinical trial

 

Companies Mentioned

GlaxoSmithKline Plc, Hutchison 3G UK Limited, Informa plc, Janssen Pharmaceuticals, Inc.

 

To order this report:

Drug_Discovery_and_Development Industry: Optimization of Comparative Efficacy Trials

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Leading Researchers Outline Principles for Conduct of Comparative Effectiveness Research
2. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
3. MedQIA unique CAD algorithm for Quantitation of lung involvement in diffuse lung disease used as treatment efficacy end point in study to be reported at the ERS Annual Conference in Vienna, Austria: September 1-5, 2012
4. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
5. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
6. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
7. Synteract Sponsoring and Presenting at Outsourcing in Clinical Trials Southeast Conference
8. HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs Second Generation HIV Vaccine
9. Berg Pharma presents at ASCO, poised to lead field in cancer metabolism with Phase II trials of BPM 31510
10. New Report Shows Ohio Clinical Trials Benefit Patients, the Economy and Science
11. PLC Systems Secures Additional Financing For US Clinical Trials And General Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... YORK , April 28, 2016  While ... notably complement the company,s valve repair and stent ... move also places Abbott more firmly into patient ... of the fastest growing device areas, with double-digit ... its recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... NEW YORK , April 28, 2016  The ... reached 275 million dollars, according to Kalorama Information and ... includes typing, immunoassays and nucleic acid testing.  The healthcare ... had made progress in developing blood collection stations and ... was made in Kalorama Information,s report, Blood ...
(Date:4/28/2016)... JERUSALEM , April 28, 2016 ... ), a clinical-stage pharmaceutical company focused on the development of ... participate in the upcoming PIONEERS 2016 conference, presented by ... 5, 2016 in New York . ... overview at the conference. Presentation Details:   ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... 2016 , ... Saturday, April 30, marks World Veterinary Day, ... health. The World Veterinary Association (WVA) and the World Organization for Animal Health ... with a One Health focus, which emphasizes how veterinarians pursue continuing education opportunities ...
(Date:4/29/2016)... ... April 30, 2016 , ... World Patent Marketing ... Up Springboard, an automotive invention that improves the storage features of a pick ... billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Over ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula ... brain and mood optimization products to the store is just one more way ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... more flexibility in repaying their loans, more information about their loan terms and ... total outstanding student loan debt, including federal and private loans, has reached $1.3 ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition ... Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making ...
Breaking Medicine News(10 mins):